05/2023
Vaccentis attends LSX conference in London and presents the core business strategy for the oncological…
04/2023
Vaccentis engages with Dr. Claudia Haslinger as external consultant, an expert in Pharma/Biotech, to oversee…
03/2023
Vaccentis attends the Sachs conference and Bio Europe Spring in Basel to present the core…
02/2023
The preclinical studies in cooperation with the University Hospital Vienna are continued in 2023. A…
01/2023
In January 2023, Dr. Ingrid Rauter was appointed Head of R&D and CMO and thus…
12/2022
In December 2022, a Family & Friends funding round was successfully completed to secure continued…
11/2022
The preclinical studies in cooperation with the University Hospital Vienna were consistently continued in 2022…
-
10/2022
In October 2022, a strategy meeting and advisory board took place in Vienna, in which…
-
09/2022
FBM-Pharma was subjected to an extensive evaluation with regard to cost and efficiency optimization and…
-
07/2022
In July 2022, Martin Munte was appointed CEO of Vaccentis. Martin Munte is a recognized…
-
05/2022
In May 2022, three top-class entrepreneurs, Matthias Oertle, Marcel Frei and Subhasis Roy, were appointed…
-
02/2022
For the main component of the growth strategy, the oncological tumor vaccine VCC-001 in the…
